ArticleInternational journal of hematology2023
Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
Hideki Nakayama et al.PubMed ↗Publisher ↗
No numbers read from the abstract.